Noble’s Hospital, operated by Manx Care on the Isle of Man, has formally detailed its medicinal cannabis policy for patients admitted for treatment. This policy, introduced in January 2025 and currently under review, outlines the procedures for patients to continue using prescribed cannabis-based medicinal products while receiving inpatient care, as confirmed by Health and Social Care Minister Claire Christian during a recent Tynwald sitting.
The development follows previous discussions in Tynwald regarding hospital protocols for medicinal cannabis patients, as previously reported by Hemp Gazette. The current policy aims to provide clarity on the management and administration of these products within the hospital environment.
Framework for Medicinal Cannabis Policy
Manx Care’s policy categorises cannabis-based medicinal products into three distinct groups to guide their management:
- Licensed Medicines: These are products with established UK or international marketing approval. Patients already prescribed these through NHS specialists are generally expected to continue receiving them during their hospital admission.
- Specialist Prescribed Medicines: This category includes products produced under recognised quality standards but without full marketing approval. If patients bring these into the hospital, they are stored as controlled drugs and recorded in hospital registers. In specific clinical circumstances, patients may be permitted to self-administer these medicines under supervision. Prerequisites for self-administration include correct labelling, valid expiry dates, and clinical suitability as determined by medical staff.
- Unlicensed Products: These are products that do not meet recognised quality standards. The policy implies a more restrictive approach to their use within the hospital setting, though specific details on their management were not extensively detailed in the public statement.
Minister Christian stated, “These medicines will be stored according to their legal class,” underscoring the regulatory compliance required for all categories.
Administration Guidelines and Site Restrictions
A key aspect of the medicinal cannabis policy addresses the method of administration, particularly concerning inhalation. The hospital maintains a strict no-smoking policy, which extends to the use of cannabis-based products. Consequently, forms of medicinal cannabis intended for smoking or vaping are not supported for self-administration on-site.
The rationale for this restriction is to prevent passive inhalation by staff or other patients, aligning with the hospital’s smoke-free environment. However, the policy acknowledges certain exceptions:
- In specific circumstances, arrangements may be made for patients to be accompanied outside the hospital building.
- This allowance for off-site use of vaping or smoking products is contingent on the patient’s clinical condition and the availability of staff to supervise.
This provision indicates a pragmatic approach to patient needs while upholding institutional health and safety standards, according to a report from iomtoday.co.im.
Transparency and Future Policy Publication
Minister Christian acknowledged the inherent complexity of existing hospital policies. Manx Care is actively working to enhance clarity by publishing key policies in plain language for both patients and the wider public. This initiative aims to improve accessibility and understanding of the regulations governing patient care, including those pertaining to medicinal cannabis.
The Minister noted the substantial volume of policies, stating, “We are gradually picking the most important [policies] and looking to get those published, but there are 500 to 600 of them to go through.” This ongoing effort suggests a commitment to greater transparency in healthcare operations on the Isle of Man.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
